ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

AKBA Akebia Therapeutics Inc

1.3303
0.0003 (0.02%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Akebia Therapeutics Inc AKBA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.0003 0.02% 1.3303 18:10:40
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.32 1.29 1.35 1.34 1.33
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
02/4/202415:05PRNUSAkebia Therapeutics Reports Inducement Grants Under Nasdaq..
27/3/202419:26PRNUSAkebia Receives FDA Approval of Vafseo® (vadadustat) Tablets..
14/3/202415:15PRNUSAkebia Therapeutics Reports Fourth Quarter and Full Year..
11/3/202416:05PRNUSAkebia Therapeutics to Report Fourth Quarter and Full Year..
01/3/202416:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202416:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202416:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202416:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202415:05PRNUSAkebia Therapeutics Reports Inducement Grants Under Nasdaq..
29/2/202417:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202417:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202417:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202417:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202415:32EDGAR2Form 144 - Report of proposed sale of securities
29/2/202415:28EDGAR2Form 144 - Report of proposed sale of securities
29/2/202415:27EDGAR2Form 144 - Report of proposed sale of securities
27/2/202417:19EDGAR2Form 144 - Report of proposed sale of securities
27/2/202417:14EDGAR2Form 144 - Report of proposed sale of securities
27/2/202417:11EDGAR2Form 144 - Report of proposed sale of securities
13/2/202407:00EDGAR2Form 8-K - Current report
02/2/202415:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:05PRNUSAkebia Therapeutics Reports Inducement Grants Under Nasdaq..
01/2/202415:52EDGAR2Form 144 - Report of proposed sale of securities
30/1/202415:33EDGAR2Form S-8 - Securities to be offered to employees in employee..
30/1/202407:05EDGAR2Form 8-K - Current report
30/1/202407:00PRNUSAkebia Secures $55 Million Term Loan Financing
18/1/202416:21EDGAR2Form 3 - Initial statement of beneficial ownership of..
09/1/202407:30PRNUSAkebia Therapeutics Announces Appointment of Nicholas Grund..
08/1/202415:08EDGAR2Form 8-K - Current report
08/1/202407:02EDGAR2Form 8-K - Current report
02/1/202415:30PRNUSAkebia Therapeutics Reports Inducement Grants Under Nasdaq..
20/12/202307:00PRNUSAkebia Therapeutics to Present at the 42nd Annual J.P...
18/12/202315:07EDGAR2Form 8-K - Current report
01/12/202315:05PRNUSAkebia Therapeutics Reports Inducement Grants Under Nasdaq..
21/11/202316:07EDGAR2Form 8-K - Current report
20/11/202307:00PRNUSAkebia Therapeutics to Present at Piper Sandler Healthcare..
08/11/202306:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202306:33EDGAR2Form 8-K - Current report
08/11/202306:30PRNUSAkebia Therapeutics Reports Third Quarter 2023 Financial..
02/11/202315:34EDGAR2Form 8-K - Current report
02/11/202315:30PRNUSAkebia Therapeutics Announces Favorable Payment Term..
01/11/202315:05PRNUSAkebia Therapeutics Reports Inducement Grants Under Nasdaq..
31/10/202307:00PRNUSAkebia Therapeutics to Report Third Quarter 2023 Financial..
25/10/202315:06EDGAR2Form 8-K - Current report

Su Consulta Reciente

Delayed Upgrade Clock